clinical trial · NCT04910386
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
3D Medicines (Sichuan) Co., Ltd.·phase2·not yet recruiting·n = 126
Biliary Tract NeoplasmsEnvafolimab plus Gemcitabine&CisplatinGemcitabine&Cisplatin
brief summary
This is a Randomized, Open-Label, Multicenter Phase 2 Study to access the efficacy and safety of Envafolimab in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients with Locally Advanced or Metastatic Biliary Tract Cancers
started
Jun 1, 2027
primary completion
Jun 1, 2029
completion
Dec 1, 2029
last updated
Mar 25, 2026
official title
A Randomized, Open-Label, Multicenter Phase 2 Study of Envafolimab in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients With Locally Advanced or Metastatic Biliary Tract Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol